Concepedia

Frederic Mack

FM

16

Publications

1.2K

Citations

14

H-Index

2011

Active since

Affiliations

University of Bonn(Current)

Goethe University Frankfurt

University of Cologne

Technische Universität Dresden

Leipzig University

Frederic Mack is an author at University of Bonn specializing in glioma, high-grade gliomas, and neuro-oncology.

ORCID

Top concepts

Publications per year

2011–2019

16

Publications

16

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 556 citations · Full text

, , +13

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Ulrich Herrlinger, Niklas Schäfer, Astrid Weyerbrock et al. · Journal of Clinical Oncology · 2016 · 194 citations

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET

Sied Kebir, Rolf Fimmers, Norbert Galldiks et al. · Clinical Cancer Research · 2015 · 125 citations

Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide

Moritz Stuplich, Dariusch R. Hadizadeh, K. Kuchelmeister et al. · Journal of Clinical Oncology · 2012 · 57 citations

, , +7

Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

Johannes Weller, Theophilos Tzaridis, Frederic Mack et al. · The Lancet Oncology · 2019 · 43 citations

, , +14

Rows per page

1–5 of 16